FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasamon, Yvette L., de Claro, R. Angelo, Wang, Yaping, Shen, Yuan Li, Farrell, Ann T., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423515/
https://www.ncbi.nlm.nih.gov/pubmed/28438889
http://dx.doi.org/10.1634/theoncologist.2017-0004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423515/
https://www.ncbi.nlm.nih.gov/pubmed/28438889
http://dx.doi.org/10.1634/theoncologist.2017-0004

Ejemplares similares